|
1
|
Antonia SJ, Villegas A, Daniel D, Vicente
D, Murakami S, Hui R, Yokoi T, Chiappori A, Lee KH, de Wit M, et
al: Durvalumab after chemoradiotherapy in stage III non-small-cell
lung cancer. N Engl J Med. 377:1919–1929. 2017.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Antonia SJ, Villegas A, Daniel D, Vicente
D, Murakami S, Hui R, Kurata T, Chiappori A, Lee KH, de Wit M, et
al: Overall survival with durvalumab after chemoradiotherapy in
stage III NSCLC. N Engl J Med. 379:2342–2350. 2018.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Toyooka S, Kiura K, Takemoto M, Oto T,
Takigawa N, Fujiwara T, Miyoshi S and Date H: Long-term outcome of
induction chemoradiotherapy with docetaxel and cisplatin followed
by surgery for non-small-cell lung cancer with mediastinal lymph
node metastasis. Interact Cardiovasc Thorac Surg. 14:565–569.
2012.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Albain KS, Swann RS, Rusch VW, Turrisi AT
III, Shepherd FA, Smith C, Chen Y, Livingston RB, Feins RH, Gandara
DR, et al: Radiotherapy plus chemotherapy with or without surgical
resection for stage III non-small-cell lung cancer: A phase III
randomised controlled trial. Lancet. 374:379–386. 2009.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Na F, Wang J, Li C, Deng L, Xue J and Lu
Y: Primary tumor standardized uptake value measured on
F18-Fluorodeoxyglucose positron emission tomography is of
prediction value for survival and local control in non-small-cell
lung cancer receiving radiotherapy: Meta-analysis. J Thorac Oncol.
9:834–842. 2014.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Liu J, Dong M, Sun X, Li W, Xing L and Yu
J: Prognostic value of 18F-FDG PET/CT in surgical
non-small cell lung cancer: A meta-analysis. PLoS One.
11(e0146195)2016.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Nair VS, Krupitskaya Y and Gould MK:
Positron emission tomography 18F-fluorodeoxyglucose
uptake and prognosis in patients with surgically treated, stage I
non-small cell lung cancer: A systematic review. J Thorac Oncol.
4:1473–1479. 2009.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Im HJ, Bradshaw T, Solaiyappan M and Cho
SY: Current methods to define metabolic tumor volume in positron
emission tomography: Which one is better? Nucl Med Mol Imaging.
52:5–15. 2018.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Park SY, Cho A, Yu WS, Lee CY, Lee JG, Kim
DJ and Chung KY: Prognostic value of total lesion glycolysis by
18F-FDG PET/CT in surgically resected stage IA non-small
cell lung cancer. J Nucl Med. 56:45–49. 2015.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Shrestha S, Higuchi T, Shirai K, Tokue A,
Shrestha S, Saitoh JI, Hirasawa H, Ohno T, Nakano T and Tsushima Y:
Prognostic significance of semi-quantitative FDG-PET parameters in
stage I non-small cell lung cancer treated with carbon-ion
radiotherapy. Eur J Nucl Med Mol Imaging. 47:1220–1227.
2019.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Satoh Y, Onishi H, Nambu A and Araki T:
Volume-based parameters measured by using FDG PET/CT in patients
with stage I NSCLC treated with stereotactic body radiation
therapy: Prognostic value. Radiology. 270:275–281. 2014.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Grootjans W, Usmanij EA, Oyen WJ, van der
Heijden EH, Visser EP, Visvikis D, Hatt M, Bussink J and de
Geus-Oei LF: Performance of automatic image segmentation algorithms
for calculating total lesion glycolysis for early response
monitoring in non-small cell lung cancer patients during
concomitant chemoradiotherapy. Radiother Oncol. 119:473–479.
2016.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Machtay M, Duan F, Siegel BA, Snyder BS,
Gorelick JJ, Reddin JS, Munden R, Johnson DW, Wilf LH, DeNittis A,
et al: Prediction of survival by [18F]fluorodeoxyglucose
positron emission tomography in patients with locally advanced
non-small-cell lung cancer undergoing definitive chemoradiation
therapy: Results of the ACRIN 6668/RTOG 0235 trial. J Clin Oncol.
20:3823–3830. 2013.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Salavati A, Duan F, Snyder BS, Wei B,
Houshmand S, Khiewvan B, Opanowski A, Simone CB II, Siegel BA,
Machtay M and Alavi A: Optimal FDG PET/CT volumetric parameters for
risk stratification in patients with locally advanced non-small
cell lung cancer: Results from the ACRIN 6668/RTOG 0235 trial. Eur
J Nucl Med Mol Imaging. 44:1969–1983. 2017.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Hyun SH, Choi JY, Kim K, Kim J, Shim YM,
Um SW, Kim H, Lee KH and Kim BT: Volume-based parameters of
(18)F-fluorodeoxyglucose positron emission tomography/computed
tomography improve outcome prediction in early-stage non-small cell
lung cancer after surgical resection. Ann Surg. 257:364–370.
2013.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Hyun SH, Ahn HK, Kim H, Ahn MJ, Park K,
Ahn YC, Kim J, Shim YM and Choi JY: Volume-based assessment by
(18)F-FDG PET/CT predicts survival in patients with stage III
non-small-cell lung cancer. Eur J Nucl Med Mol Imaging. 41:50–58.
2014.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Hyun SH, Ahn HK, Ahn MJ, Ahn YC, Kim J,
Shim YM and Choi JY: Volume-based assessment with
18F-FDG PET/CT improves outcome prediction for patients
with stage IIIa-N2 non-small cell lung cancer. AJR Am J Roentgenol.
205:623–628. 2015.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Ogata T, Katsui K, Yoshio K, Ihara H,
Katayama N, Soh J, Kuroda M, Kiura K, Maeda Y, Toyooka S and
Kanazawa S: Dose-volume parameters predict radiation pneumonitis
after surgery with induction concurrent chemoradiotherapy for
non-small cell lung cancer. Acta Med Okayama. 72:507–513.
2018.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Katsui K, Ogata T, Watanabe K, Katayama N,
Kuroda M, Kiura K, Hiraki T, Maeda Y, Toyooka S and Kanazawa S:
Radiation pneumonitis after definitive concurrent chemoradiotherapy
with cisplatin/docetaxel for non-small cell lung cancer: Analysis
of dose-volume parameters. Cancer Med. 9:4540–4549. 2020.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Segawa Y, Kiura K, Takigawa N, Kamei H,
Harita S, Hiraki S, Watanabe Y, Sugimoto K, Shibayama T, Yonei T,
et al: Phase III trial comparing docetaxel and cisplatin
combination chemotherapy with mitomycin, vindesine, and cisplatin
combination chemotherapy with concurrent thoracic radiotherapy in
locally advanced non-small-cell lung cancer: OLCSG 0007. J Clin
Oncol. 28:3299–3306. 2010.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Takigawa N, Kiura K, Hotta K, Hosokawa S,
Nogami N, Aoe K, Gemba K, Fujiwara K, Harita S, Takemoto M, et al:
A phase I study of S-1 with concurrent thoracic radiotherapy in
elderly patients with localized advanced non-small cell lung
cancer. Lung Cancer. 71:60–64. 2011.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Im HJ, Pak K, Cheon GJ, Kang KW, Kim SJ,
Kim IJ, Chung JK, Kim EE and Lee DS: Prognostic value of volumetric
parameters of (18)F-FDG PET in non-small-cell lung cancer: A
meta-analysis. Eur J Nucl Med Mol Imaging. 42:241–251.
2015.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Huang W, Fan M, Liu B, Fu Z, Zhou T, Zhang
Z, Gong H and Li B: Value of metabolic tumor volume on repeated
18F-FDG PET/CT for early prediction of survival in
locally advanced non-small cell lung cancer treated with concurrent
chemoradiotherapy. J Nucl Med. 55:1584–1590. 2014.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Keyes JW Jr: SUV: Standard uptake or silly
useless value? J Nucl Med. 36:1836–1839. 1995.PubMed/NCBI
|
|
25
|
Boellaard R, Krak NC, Hoekstra OS and
Lammertsma AA: Effects of noise, image resolution, and ROI
definition on the accuracy of standard uptake values: A simulation
study. J Nucl Med. 45:1519–1527. 2004.PubMed/NCBI
|
|
26
|
Denis F, Lethrosne C, Pourel N, Molinier
O, Pointreau Y, Domont J, Bourgeois H, Senellart H, Trémolières P,
Lizée T, et al: Randomized trial comparing a web-mediated follow-up
with routine surveillance in lung cancer patients. J Natl Cancer
Inst. 109:2017.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Wahl RL, Jacene H, Kasamon Y and Lodge MA:
From RECIST to PERCIST: Evolving considerations for PET response
criteria in solid tumors. J Nucl Med. 50 (Suppl 1):122S–150S.
2009.PubMed/NCBI View Article : Google Scholar
|
